Induction and Impact of Anti-Drug Responses Elicited by a Human Recombinant Coagulation Factor FXaI16L in Preclinical Species
This paper presents a systemic investigation of ADA development and ADA impact of a human coagulation factor in nonclinical species during drug development and provides insights into potential implications in human if a similar ADA occurs. FXaI16L-induced ADA response was characterized in monkey, mouse, rat, and dog in different studies, and ADA effects on pharmacokinetic and/or pharmacodynamics of FXaI16L were further examined in ADA-negative and ADA-positive animals. After repeated administrations, FXaI16L elicited a dose and exposure day-dependent ADA response which ranged from no response to a transient or persistent response. Increase in exposure day and increase in dose generally enhanced ADA incidence except for a decrease in ADA incidence was observed in monkeys after repeated high-dose administrations. The observable ADA impact on pharmacokinetics was only found in some ADA+ animals and included decrease in clearance and increase in systemic exposure but no increase in half-life. In addition, no or limited effect on pharmacodynamics by ADA was observed. The earliest ADA response was observed after three exposure days, marked elevation of drug exposure was observed in some animals at log titer > 2.0, and the highest antibody titer excited was about 4 (Log10) in all species. A correlation between ADA induction and accumulative exposure after various repeat treatments in different species was found for FXaI16L. In addition, potential immunogenicity risk and mitigation of ADA in clinics are discussed.
KEY WORDSanti-drug antibody coagulation factor exposure day FXaI16L hemophilia inhibitor neutralizing antibody
Area under the curve
Maximum observed concentration
Factor eight inhibitor bypassing agent (anti-inhibitor coagulant complex)
Active coagulation factor X
All of the authors are Pfizer employees and FXaI16 is a Pfizer clinical candidate. We thank all the support and guidance from the Pfizer FXaI16L development team. We also thank all the colleagues involved in development of FXaI16L in Pfizer whose dedication made all the studies possible.
- 3.Tovey MG. Immunogenicity and other problems associated with the use of biopharmaceuticals. Ther Adv Drug Safety. 2011;3:133–28.Google Scholar
- 5.Scgnolari C, Bellomi F, Turriziani O, Bagnato F, Tomassini V, Lavolpe V, et al. Neutralizing and binding antibodies to IFN-beta: relative frequency in relapsing-remitting multiple sclerosis patients treated with different IFN-beta preparations. J Interf Cytokine Res. 2002;22:207–13.CrossRefGoogle Scholar
- 11.Mahlangu JN, Koh PL, Ng HJ, Lissitchkov T, Hardtke M, Schroeder J. The TRUST trial: anti-drug antibody formation in a patient with hemophilia with inhibitors after receiving the activated factor VII product bay 86–6150. In: Presented at 55th annual meeting of the American Society of Hematology 2013; Abstrat 573.Google Scholar
- 16.Bolt M, Hua F, Brenneman K, Graves J, Arkin S, Criswell K. Evaluation of potential safety biomarkers for monitoring thrombogenic potential of FXaI16L. Blood. 2014;124:4237.Google Scholar
- 18.Reinisch W. Eser A, Schreiber S, Kim H, Mould D. Clinical: therapy and observation. Reduction of dosing intervals is the preferable dose optimisation strategy for infliximab to suppress formation of anti-drug antibodies. 2018;401.Google Scholar